tetano
Editor, Senior Moderator
Int J Surg
. 2021 Dec 30;106204.
doi: 10.1016/j.ijsu.2021.106204. Online ahead of print.
Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks
Manish Dhawan[SUP] 1 [/SUP], Priyanka[SUP] 2 [/SUP], Manisha Parmar[SUP] 3 [/SUP], Steffy Angural[SUP] 4 [/SUP], Om Prakash Choudhary[SUP] 5 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in a catastrophic pandemic and severely impacted people's livelihoods worldwide. In addition, the emergence of SARS-CoV-2 variants has posed a severe threat to humankind. Due to the dearth of therapeutic options during the commencement of the pandemic, convalescent plasma therapy (CPT) played a significant part in the management of patients with severe form of COVID-19. Several recent studies have proposed various protective effects of CPT, such as antiviral, anti-inflammatory, anti-thrombotic, and immunomodulatory actions, curtailing the devastating consequences of the SARS-CoV-2 infection. On the contrary, several clinical studies have raised some serious concerns about the effectiveness and reliability of CPT in the management of patients with COVID-19. The protective effects of CPT in severely ill patients are yet to be proved. Moreover, the emergence of SARS-CoV-2 variants has raised concerns about the effectiveness of CPT against COVID-19. Therefore, to establish concrete evidence of the efficacy of CPT and adjudicate its inclusion in the management of COVID-19, an updated review of present literature is required, which could help in the development of an efficient therapeutic regimen to treat COVID-19 amid the emergence of new viral variants.
Keywords: COVID-19; Convalescent plasma therapy; Effectiveness; SARS-CoV-2; Safety; Variants.
. 2021 Dec 30;106204.
doi: 10.1016/j.ijsu.2021.106204. Online ahead of print.
Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks
Manish Dhawan[SUP] 1 [/SUP], Priyanka[SUP] 2 [/SUP], Manisha Parmar[SUP] 3 [/SUP], Steffy Angural[SUP] 4 [/SUP], Om Prakash Choudhary[SUP] 5 [/SUP]
Affiliations
- PMID: 34974199
- DOI: 10.1016/j.ijsu.2021.106204
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in a catastrophic pandemic and severely impacted people's livelihoods worldwide. In addition, the emergence of SARS-CoV-2 variants has posed a severe threat to humankind. Due to the dearth of therapeutic options during the commencement of the pandemic, convalescent plasma therapy (CPT) played a significant part in the management of patients with severe form of COVID-19. Several recent studies have proposed various protective effects of CPT, such as antiviral, anti-inflammatory, anti-thrombotic, and immunomodulatory actions, curtailing the devastating consequences of the SARS-CoV-2 infection. On the contrary, several clinical studies have raised some serious concerns about the effectiveness and reliability of CPT in the management of patients with COVID-19. The protective effects of CPT in severely ill patients are yet to be proved. Moreover, the emergence of SARS-CoV-2 variants has raised concerns about the effectiveness of CPT against COVID-19. Therefore, to establish concrete evidence of the efficacy of CPT and adjudicate its inclusion in the management of COVID-19, an updated review of present literature is required, which could help in the development of an efficient therapeutic regimen to treat COVID-19 amid the emergence of new viral variants.
Keywords: COVID-19; Convalescent plasma therapy; Effectiveness; SARS-CoV-2; Safety; Variants.
